TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A placebo-controlled phase I trial found that one injection of CIDEBsiRNA was followed by substantial liver-fat reductions over 36 weeks in adults with MASLD. The results are early: the study was small, was not designed to establish statistical efficacy, and included few indicators of advanced liver disease.
A single injection of CIDEBsiRNA was followed by large reductions in liver fat among adults with metabolic dysfunction-associated steatotic liver disease (MASLD), according to results from a 40-person, placebo-controlled phase I trial. At the highest dose, average liver fat fell 80.3% from baseline by week 36; the early findings do not establish whether the treatment prevents liver damage or improves long-term health.
Participants were assigned to one of four doses of the small interfering RNA (siRNA) therapy, also called ALN-CIDEB, or to placebo. At week 36, 62% of treated participants had liver fat below 5%, the trial’s definition of normalization; none of the placebo group did. A relative liver-fat reduction of at least 30%—a threshold associated with histological improvement—was reached by 93% of treated participants and 10% of those given placebo.
Average liver-fat changes from baseline to week 36 were 57.8% lower at 15 mg, 59.3% lower at 60 mg, 65.2% lower at 200 mg and 80.3% lower at 600 mg. The placebo group had a 2.9% reduction. The report said mean blood levels of alanine aminotransferase (ALT), a liver enzyme, fell 32% from baseline to week 12 across treated participants, while the placebo group had a 5% increase. At week 36, the 600-mg group’s mean ALT was down 36.5%; placebo was up 6.6%.
Overall treatment-emergent adverse events occurred in 87% of the CIDEBsiRNA group and 90% of the placebo group. Events considered related to the study drug were reported in 10% of treated participants and none receiving placebo. Upper respiratory tract infections occurred in 20% of both groups. The findings were presented by Jörg Täubel of Richmond Pharmacology at the American Association for the Study of Liver Diseases’ annual meeting in Denver and published simultaneously in the New England Journal of Medicine.
A Single Dose, Measured Over Months
The findings offer an early signal that targeting a liver-fat pathway with siRNA could produce a sustained change after one dose. A treatment that works for months between injections could be convenient, but the trial does not establish how often future patients would need treatment or whether lowering liver fat in this way reduces the risk of cirrhosis, liver failure or cancer.
MASLD affects a large population: the source report estimates as many as 85 million U.S. adults have the condition, and says no drugs are specifically indicated for MASLD. Care commonly includes changes to diet, exercise and weight. An estimated 25% to 30% of people with MASLD develop metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis and other serious liver problems. Larger studies will need to show whether CIDEBsiRNA benefits patients beyond changes in imaging and enzyme measurements.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Garmin Forerunner 935 GPS Running and Multisport Watch, Black
Therabody TheraFace Mask Glo Cordless LED Skincare Mask
As an affiliate, we earn on qualifying purchases.
How CIDEBsiRNA Targets Liver Fat
CIDEBsiRNA is designed to reduce messenger RNA made by the CIDEB gene in liver cells. That gene helps regulate the size of fat droplets in the liver. The report notes that people with loss-of-function CIDEB mutations have lower risks of MASLD, MASH and cirrhosis; the drug seeks to act on the same biological target through an RNA-based treatment.
Trial participants had MASLD, a body mass index of 30 to 40, and liver fat of at least 8.5%. Their average age was 40.4 years, average BMI was 34.2, and average liver fat measured by MRI was 14.3%. A quarter had type 2 diabetes. Most did not have elevated liver-enzyme levels at the start, and the group generally did not have evidence of fibrosis, limiting how closely it represents patients with more advanced disease.
“We know that if we manage to reduce the amount of fat in the liver, this correlates very favorably with clinical outcomes.”
— Jörg Täubel, Richmond Pharmacology, presenting at the AASLD annual meeting
Limits of the Phase I Evidence
The study included only 40 participants and was not powered for statistical inference. The reported percentages and dose-group changes are early results, not definitive proof of treatment effect. Similar overall adverse-event rates between groups also do not rule out uncommon or longer-term risks that a small trial cannot reliably identify.
It is also unclear whether the liver-fat and ALT changes will translate into less inflammation, fibrosis or liver-related illness. Most participants lacked elevated liver enzymes or fibrosis at baseline, so the findings may not apply to people with more advanced MASLD or MASH. The report does not provide enough evidence to establish long-term durability, the best dose, or how a treatment schedule would work outside a trial.
Larger Trials Will Test Outcomes
CIDEBsiRNA has moved into a phase II trial for MASH and a phase III trial for MASLD, according to the report. These later studies are expected to examine the treatment in larger groups and provide more information about safety and effects across different disease stages.
Readers should look for the trials’ reported enrollment, follow-up period and endpoints, including whether they assess fibrosis or other measures beyond liver fat. Until those results are available and reviewed, CIDEBsiRNA remains investigational; the phase I findings alone do not establish it as an approved or proven treatment.
Key Questions
What is CIDEBsiRNA?
CIDEBsiRNA, also called ALN-CIDEB, is an investigational small interfering RNA therapy designed to target messenger RNA produced by the CIDEB gene in liver cells.
How much did liver fat change in the trial?
By week 36, average liver fat was down from baseline by 57.8% to 80.3% across the four dose groups. The placebo group had a 2.9% reduction. These are phase I results from a 40-person study.
Did the treatment normalize liver fat for everyone?
No. At week 36, 62% of treated participants had liver fat below 5%, compared with none in the placebo group. The report also described normalization in four out of five participants by week 24 in Täubel’s meeting remarks.
Does this prove CIDEBsiRNA prevents liver damage?
No. The study reported changes in liver fat and ALT, but it was not designed to establish long-term clinical benefit. Whether treatment prevents fibrosis, cirrhosis or other complications remains unknown.
What happens next for the drug?
The source report says CIDEBsiRNA has entered phase II testing for MASH and phase III testing for MASLD. Those trials will be needed to clarify safety, effectiveness and which patients may benefit.
Source: medpagetoday.com
